biostudies-literatureUnknown32(10)Inoue S<h4>Objectives</h4>The association between the response to first-line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real-world data.<h4>Methods</h4>We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial-response group was defined as patients with complete response or partial response as the best response to first-line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first-line chemotherapy.<h4>Results</h4>Seven patients (7.0%) achieved compInternational journal of urology : official journal of the Japanese Urological Association1449-1459https://www.ebi.ac.uk/biostudies/studies/S-EPMC12503202biostudies-literatureResponse to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.PMC12503202Nagasaka YIto FYuba TInoue SOmi TYuguchi YKawanishi HAkamatsu SHayakawa ATochigi KKobayashi MShamoto NfalseResponse to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.<h4>Objectives</h4>The association between the response to first-line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real-world data.<h4>Methods</h4>We retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial-response group was defined as patients with complete response or partial response as the best response to first-line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first-line chemotherapy.<h4>Results</h4>Seven patients (7.0%) achieved comp2025-01-01T00:00:00Z2025 Oct2026-06-04T06:53:32.706Z2026-05-06T03:13:31.824ZS-EPMC125032024060039510.1111/iju.70162